中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

未开盘 04-23 16:08:51

3.840

+0.010

+0.26%

最高3.930	最低3.810	成交量9,128万
今开3.900	昨收3.830	日振幅3.13%
总市值720.77亿	流通市值720.77亿	总股本187.70亿
成交额3.52亿	换手率0.49%	流通股本187.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":3.84,"timestamp":1745395731012,"preClose":3.83,"halted":0,"volume":91284504,"delay":0,"floatShares":18770000000,"shares":18770000000,"eps":0.20370315654704177,"marketStatus":"未开盘","change":0.01,"latestTime":"04-23 16:08:51","open":3.9,"high":3.93,"low":3.81,"amount":351620588,"amplitude":0.031332,"askPrice":3.84,"askSize":1601000,"bidPrice":3.83,"bidSize":1300000,"shortable":3,"etf":0,"ttmEps":0.20364033613967028,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745458200000},"marketStatusCode":0,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":3.83,"dividendRate":0.01824,"openAndCloseTimeList":[[1745371800000,1745380800000],[1745384400000,1745395200000]],"volumeRatio":1.0640674798122756,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.5063,"impliedVolPercentile":0.9306},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2529021578","title":"中国生物制药产品两大新适应症上市获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529021578","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529021578?lang=zh_cn&edition=full","pubTime":"2025-04-23 17:15","pubTimestamp":1745399739,"startTime":"0","endTime":"0","summary":"人民财讯4月23日电，4月23日，中国生物制药（01177.HK）旗下1类创新药“贝莫苏拜单抗+安罗替尼胶囊”组合的两大新适应症上市申请双双获受理，该组合目前已获批+申报上市的适应症已达5个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504233385916088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1589","BK1521","01177","BK1191"],"gpt_icon":0},{"id":"2529278955","title":"中国生物制药产品两大新适应症上市获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529278955","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529278955?lang=zh_cn&edition=full","pubTime":"2025-04-23 17:05","pubTimestamp":1745399141,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","01177","BK1521","159992","BK1191","BK1574","BK1515","BK1589","06978"],"gpt_icon":0},{"id":"2529321847","title":"中国生物制药04月22日主力净流入2029万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529321847","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529321847?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:17","pubTimestamp":1745309835,"startTime":"0","endTime":"0","summary":"04月22日, 中国生物制药股价涨4.36%，报收3.83元，成交金额4.20亿元，换手率0.59%，振幅5.45%，量比1.29。中国生物制药今日主力资金净流入2029万元，上一交易日主力净流出59万元。该股近5个交易日上涨6.15%，主力资金累计净流入4653万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.60亿元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171650a4623c98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171650a4623c98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","01177","BK1191","BK1515","BK1521"],"gpt_icon":0},{"id":"1109553900","title":"异动解读 | 中国生物制药参与设立10亿元基金，股价盘中大涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109553900","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109553900?lang=zh_cn&edition=full","pubTime":"2025-04-22 15:04","pubTimestamp":1745305472,"startTime":"0","endTime":"0","summary":"中国生物制药今日盘中大涨5.18%，引起市场广泛关注。消息面上，中生引领（上海）私募投资基金于今日揭牌成立，中国生物制药作为首轮出资人之一参与其中。该基金目标总规模达10亿元，首轮规模为5亿元。中国生物制药参与设立该基金，彰显了公司在生物医药创新领域的战略布局和长期发展眼光。投资者对此反应积极，推动公司股价显著上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 中国生物制药参与设立10亿元基金，股价盘中大涨5.18%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"gpt_icon":0},{"id":"2529310201","title":"中国生物制药盘中异动 下午盘大幅拉升5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529310201","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529310201?lang=zh_cn&edition=full","pubTime":"2025-04-22 15:02","pubTimestamp":1745305370,"startTime":"0","endTime":"0","summary":"2025年04月22日下午盘15时02分，中国生物制药股票出现异动，股价大幅拉升5.18%。中国生物制药股票所在的药品行业中，整体涨幅为1.14%。中国生物制药的TRD205率先进入临床2期研究，成为全球首个针对慢性术后神经痛并进入2期临床阶段的创新药。中国生物制药将镇痛列为四大核心治疗领域之一，2024年该领域收入达44.58亿元，占集团收入15.4%，较去年同期收入同比增加18.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042215025494ddbd93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042215025494ddbd93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1191","BK1515","BK1521","BK1589"],"gpt_icon":0},{"id":"2529678053","title":"总规模10亿元中生引领基金揭牌，浦东创投、中国生物制药等为首关出资人","url":"https://stock-news.laohu8.com/highlight/detail?id=2529678053","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529678053?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:53","pubTimestamp":1745286791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1589","161726","01177","BK1191","BK1515","399441","BK1521"],"gpt_icon":0},{"id":"2529817784","title":"全球首个！中国生物制药勇闯千亿赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2529817784","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529817784?lang=zh_cn&edition=full","pubTime":"2025-04-21 11:05","pubTimestamp":1745204708,"startTime":"0","endTime":"0","summary":"近日，中国生物制药宣布其自主研发的潜在“First-in-class”镇痛新药TRD205正式启动临床2期研究。中国生物制药的TRD205率先进入临床2期研究，成为全球首个针对慢性术后神经痛并进入2期临床阶段的创新药。中国生物制药的“镇痛布局”中国生物制药将镇痛列为四大核心治疗领域之一，2024年该领域收入达44.58亿元，占集团收入15.4%，较去年同期收入同比增加18.9%。针对术后镇痛这一临床痛点，中国生物制药通过引进与自研双轮驱动布局长效镇痛药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421111834a4606d67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421111834a4606d67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1191","BK1589","01177","BK1515"],"gpt_icon":0},{"id":"1190699518","title":"异动解读 | 中国生物制药盘中大跌5.11%，大手交易活跃，券商看好前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1190699518","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190699518?lang=zh_cn&edition=full","pubTime":"2025-04-16 13:14","pubTimestamp":1744780473,"startTime":"0","endTime":"0","summary":"周三盘中，中国生物制药股价出现显著下跌，截至下午1时01分，该股大跌5.11%，报3.53港元。尽管盘中出现大幅下跌，但市场上仍有大手交易活跃，同时券商对该公司前景保持乐观态度。盘中交易数据显示，中国生物制药早盘出现多笔大手交易。大和证券将公司目标价从3.5港元上调至4港元，并重申\"买入\"评级。研报指出，中国生物制药去年业绩表现良好，收入同比增长10.2%，主要受创新药带动；毛利率同比上升0.5个百分点；经调整净利润增长33.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 中国生物制药盘中大跌5.11%，大手交易活跃，券商看好前景","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"gpt_icon":0},{"id":"2527354832","title":"中国生物制药盘中异动 下午盘急速下跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527354832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527354832?lang=zh_cn&edition=full","pubTime":"2025-04-16 13:01","pubTimestamp":1744779694,"startTime":"0","endTime":"0","summary":"2025年04月16日下午盘13时01分，中国生物制药股票出现波动，股价快速下跌5.11%。中国生物制药股票所在的药品行业中，整体跌幅为0.67%。该信息摘要如下：大和发布研报称，中国生物制药去年受到创新药带动，收入同比增长10.2%;毛利率同比升0.5个百分点;销售及行政支出比率保持稳定于42.1%;研究开发比率升0.8个百分点;经调整净利润增33.5%。该行将中生制药下个财政年度的收入预测上调9%至12%，重申其“买入”评级，目标价由3.5港元上调至4港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416130134a6bc1a96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416130134a6bc1a96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","01177","BK1521","BK1589"],"gpt_icon":0},{"id":"2527461208","title":"中国生物制药04月15日主力净流出759万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527461208","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527461208?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:16","pubTimestamp":1744705017,"startTime":"0","endTime":"0","summary":"04月15日, 中国生物制药股价跌0.53%，报收3.72元，成交金额2.89亿元，换手率0.41%，振幅2.67%，量比0.60。中国生物制药今日主力资金净流出759万元，上一交易日主力净流入2676万元。该股近5个交易日上涨8.77%，主力资金累计净流入2888万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.37亿元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415171804a6bb0550&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415171804a6bb0550&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1191","BK1589","01177","BK1515"],"gpt_icon":0},{"id":"2527090114","title":"大和：升中国生物制药目标价至4港元 重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2527090114","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527090114?lang=zh_cn&edition=full","pubTime":"2025-04-14 15:27","pubTimestamp":1744615644,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，中国生物制药(01177)去年受到创新药带动，收入同比增长10.2%;毛利率同比升0.5个百分点;销售及行政支出比率保持稳定于42.1%;研究开发比率升0.8个百分点;经调整净利润增33.5%。该行将中生制药下个财政年度的收入预测上调9%至12%，重申其“买入”评级，目标价由3.5港元上调至4港元。该行又将集团今明两年的创新药收入预测上调4%和15%，分别至150亿和190亿元人民币。不过，该行下调集团今年的每股盈测8%，以主要反映非核心收入下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041416020894d4c1aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041416020894d4c1aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177"],"gpt_icon":0},{"id":"2527056971","title":"中国生物制药(01177)上涨4.75%，报3.75元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2527056971","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527056971?lang=zh_cn&edition=full","pubTime":"2025-04-14 14:19","pubTimestamp":1744611567,"startTime":"0","endTime":"0","summary":"4月14日，中国生物制药盘中上涨4.75%，截至14:19，报3.75元/股，成交3.01亿元。中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域具有优势。截至2024年年报，中国生物制药营业总收入288.66亿元、净利润35.0亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/14141949516393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01177","BK1589","BK1191","BK1515","BK1521"],"gpt_icon":0},{"id":"1130746707","title":"异动解读 | 中国生物制药盘中大涨5.03%，南向资金持续加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=1130746707","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130746707?lang=zh_cn&edition=full","pubTime":"2025-04-14 10:14","pubTimestamp":1744596867,"startTime":"0","endTime":"0","summary":"周一盘中，中国生物制药股价突然飙升，涨幅高达5.03%，引起市场广泛关注。这一显著涨幅可能与近期南向资金的持续流入有关。据最新数据显示，4月11日南向资金增持中国生物制药1401.80万股，截至当日收盘，港股通共持有该公司249502.26万股，占流通股的13.29%。这表明投资者对中国生物制药的信心正在增强。尽管中国生物制药在近5个交易日曾出现7.97%的跌幅，但南向资金仍保持积极态度，累计增持9232.20万股。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 中国生物制药盘中大涨5.03%，南向资金持续加仓","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"gpt_icon":0},{"id":"2527386781","title":"中国生物制药(1177.HK)：收入重回双位数增长 创新转型大踏步向前","url":"https://stock-news.laohu8.com/highlight/detail?id=2527386781","media":"第一上海","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527386781?lang=zh_cn&edition=full","pubTime":"2025-04-14 00:00","pubTimestamp":1744560000,"startTime":"0","endTime":"0","summary":"仿制药集采风险基本出清，全年实现收入168.1 亿，重回正增长。公司运营效率持续提升，全年毛利率81.5%，同比增长0.5pts。公司将继续维持研发投入力度，深化创新转型。截止2024 年底，公司创新产品数量已达17 个，并将继续以每年4-7 款获批的步伐持续扩展，为公司收入快速增长持续提供强劲动力。未来公司仿制药管线将维持稳定的投入和增长，并创造出海机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414144718a6b9b317&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414144718a6b9b317&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","01177","BK1589","BK1515","BK1191"],"gpt_icon":0},{"id":"2518762619","title":"恒指尾盘翻红，早间一度跌逾2%，中国生物制药(01177.HK)、快手(01024.HK)、农夫山泉(09633.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518762619","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518762619?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:32","pubTimestamp":1741678344,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0348766576.USD","LU1251922891.USD","LU2097828714.EUR","81024","BK1615","BK1610","BK1589","LU2097828474.EUR","HSI","01177","01024","YANG","LU2097828805.USD","BK1591","MHImain","LU1794554557.SGD","LU1981816686.USD","513600","BK1515","BK1608","BK1095","LU0348767384.USD","BK1590","02833","LU2097828557.USD","LU1720050803.USD","HSTECH","LU1770034418.SGD","HSImain","LU1719994722.HKD","BK1521","BK4614","BK1575","MCHmain","LU1303224171.USD","LU2097828631.EUR","BK1200","BK1191","HHImain","09633"],"gpt_icon":0},{"id":"2518768669","title":"中国生物制药(01177)上涨4.78%，报3.51元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2518768669","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518768669?lang=zh_cn&edition=full","pubTime":"2025-03-11 13:50","pubTimestamp":1741672249,"startTime":"0","endTime":"0","summary":"3月11日，中国生物制药盘中上涨4.78%，截至13:50，报3.51元/股，成交3.52亿元。中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域具有优势。截至2024年中报，中国生物制药营业总收入158.74亿元、净利润30.17亿元。3月20日，中国生物制药将披露2024财年年报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11135048652316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1521","BK1515","BK1589","01177","BK1191"],"gpt_icon":0},{"id":"2518535267","title":"港股异动 | 中国生物制药(01177)涨超4% 自研创新药“罗伐昔替尼”IB/IIA期临床研究结果发表于《血液》","url":"https://stock-news.laohu8.com/highlight/detail?id=2518535267","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518535267?lang=zh_cn&edition=full","pubTime":"2025-03-11 11:11","pubTimestamp":1741662694,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨超4%，截至发稿，涨4.48%，报3.5港元，成交额2.03亿港元。消息面上，3月10日，中国生物制药发布公告，该集团自主研发的国家1类创新药“罗伐昔替尼”用于治疗慢性移植物抗宿主病的Ib/IIa 期临床研究结果已发表于国际血液学领域顶级期刊《血液》。据悉，JAK和ROCK是调控免疫反应和纤维化进程的两大关键信号通路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","159992","BK1589","BK1521","BK1161","01177","06978","BK1191"],"gpt_icon":0},{"id":"2518328737","title":"中国生物制药盘中异动 急速拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518328737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518328737?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:25","pubTimestamp":1741659909,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘10时25分，中国生物制药股票出现异动，股价快速拉升5.07%。截至发稿，该股报3.520港元/股，成交量4295.63万股，换手率0.23%，振幅6.87%。中国生物制药股票所在的药品行业中，整体涨幅为0.07%。其相关个股中，三生制药、中国生物制药、中国医疗集团涨幅较大，振幅较大的相关个股有三生制药、德琪医药-B、九源基因，振幅分别为9.34%、7.67%、7.50%。中国生物制药公司简介：本集团业务覆盖医药各种研发平台、智能化生产和强大销售体系全产业链。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031110250998a3403c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031110250998a3403c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1521","BK1589","BK1191","01177"],"gpt_icon":0},{"id":"2518321337","title":"中国生物制药(01177)逆市升逾2% 罗伐昔替尼临床研究结果发表于国际顶刊《血液》","url":"https://stock-news.laohu8.com/highlight/detail?id=2518321337","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518321337?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:10","pubTimestamp":1741659050,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药 逆市上涨，截至发稿，涨2.09%，报3.42港元，成交额6830.93万港元。隔晚公司公告，公司自主研发的国家1类创新药\"罗伐昔替尼\"用于治疗慢性移植物抗宿主病的Ib/IIa期临床研究结果已发表于国际血液学领域顶级期刊《血液》。大摩对中国生物制药2024年销售额预测下降1.2%，主要源于医保限制趋严下药品Ganmei销售表现不佳。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954758","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","01177","BK1191","BK1589","BK1515"],"gpt_icon":0},{"id":"2518279342","title":"港股公告掘金 |海丰国际年度股东应占溢利10.28亿美元，同比增长93.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518279342","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518279342?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:05","pubTimestamp":1741619127,"startTime":"0","endTime":"0","summary":"【重大事项】国华(00370)附属AI集团拟与中科编易以重组方式建立一间合资公司中国生物制药(01177)：全球首创JAK/ROCK抑制剂“罗伐昔替尼(ROVADICITINIB)”IB/IIA期临床研究结果发表于《血液》翰森制药(03692)：阿美乐 (甲磺酸阿美替尼片)第三项适应症获国家药监局签发药品注册证书高视医疗(02407)全资附属公司达成MDR重要里程碑;及自研亲水性丙烯酸人工晶状体(","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00370","09863","SG9999011746.SGD","BK1521","LU1328615791.USD","IE00BHRH8C09.USD","YANG","BK1181","BK1515","HSTECH","BK1229","IE00BYQNZ168.SGD","01997","IE00BHRH8D16.HKD","BK1103","BK1119","BK1534","BK4614","BK1258","LU0229494975.USD","LU1316543674.SGD","BK1601","IE00B12V2V27.USD","IE00BYTNYN87.SGD","BK1541","BK1589","HSCEI","LU2226123227.USD","01308","LU2226123490.SGD","IE00BG0RBZ43.SGD","01177"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0637},{"period":"1month","weight":0.0847},{"period":"3month","weight":0.338},{"period":"6month","weight":0.0847},{"period":"1year","weight":0.519},{"period":"ytd","weight":0.2}],"compareEarnings":[{"period":"1week","weight":0.0482},{"period":"1month","weight":-0.0767},{"period":"3month","weight":0.1204},{"period":"6month","weight":0.072},{"period":"1year","weight":0.3116},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一间主要从事药品业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部主要从事长期及短期投资。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.409091,"avgChangeRate":0.00468},{"month":2,"riseRate":0.681818,"avgChangeRate":0.062888},{"month":3,"riseRate":0.590909,"avgChangeRate":0.049871},{"month":4,"riseRate":0.5,"avgChangeRate":0.024648},{"month":5,"riseRate":0.714286,"avgChangeRate":0.038695},{"month":6,"riseRate":0.333333,"avgChangeRate":0.000979},{"month":7,"riseRate":0.619048,"avgChangeRate":0.029709},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.01409},{"month":9,"riseRate":0.380952,"avgChangeRate":-0.016432},{"month":10,"riseRate":0.571429,"avgChangeRate":0.033241},{"month":11,"riseRate":0.52381,"avgChangeRate":0.069716},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.007225}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}